Laboratorios Farmaceuticos Rovi (FRA:41L) Tax Provision: €-50.2 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:41L Laboratorios Farmaceuticos Rovi SA FRA:41L
89 GF Score
Price €58.55
GF Value €54.02
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Tax Provision?

Laboratorios Farmaceuticos Rovi FRA:41L 89 Tax Provision is €-50.2 Mil as of Jun. 2026. GuruFocus rates FRA:41L with a GF Score™ of 89/100 and a GF Value™ of €54.02 (Fairly Valued). The stock has 2 warning signs investors should review.

Laboratorios Farmaceuticos Rovi's tax provision for the three months ended in Jun. 2026 was €-14.4 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2026 was €-50.2 Mil.

Laboratorios Farmaceuticos Rovi Tax Provision Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Tax Provision Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.55 -58.30 -50.11 -40.81 -42.90

Laboratorios Farmaceuticos Rovi Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.15 -17.69 -15.29 -2.84 -14.35
FRA:41L
89GF Score
Laboratorios Farmaceuticos Rovi SA FRA:41L
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-50.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of €-50.2 Mil mean?
Laboratorios Farmaceuticos Rovi (FRA:41L) has a Tax Provision of €-50.2 Mil as of Jun. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Tax Provision too high?
Laboratorios Farmaceuticos Rovi's current Tax Provision is €-50.2 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Tax Provision compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Tax Provision of €-50.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Tax Provision is €-50.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (FRA:41L) is currently considered Fairly Valued. The stock's GF Value™ is €54.02, compared to a current price of €58.55 — trading 8.4% above its estimated fair value. The current Tax Provision is €-50.2 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (FRA:41L), the current Tax Provision is €-50.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €58.55 is trading 8.4% above its estimated GF Value™ of €54.02. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Fairly Valued.

Key valuation signals for FRA:41L:

  • Tax Provision: €-50.2 Mil
  • GF Value™: €54.02 vs. price of €58.55 (8.4% above fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score

Get the complete analysis for FRA:41L

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.55
Price
€54.02
GF Value